Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question

Staff  |  Issue: April 2009  |  April 1, 2009

A 38-year-old female comes in for her scheduled follow-up for the diagnosis of rheumatoid arthritis. She is on celecoxib, methotrexate, folic acid, and lansoprazole. The patient reports moderate pain, swelling, and stiffness in her wrists and most finger joints every day, which is interfering with activities such as opening jars, buttoning clothing, using a computer keyboard, etc. The patient also reports generalized morning joint stiffness lasting from one to three hours on most days of the week and episodes of fatigue that are easily brought on. She has history of gastroesophageal reflux disease (GERD), but denies dyspepsia or abdominal complaints. The patient also denies fevers, headaches, chest pain, dyspnea, cough, oral ulcers, Raynaud’s phenomenon, rashes, hematochezia, insomnia, or depression. The patient is a secretary in a law firm, is married and has two young children, ages three and five years.

On examination, the patient is alert and oriented, with normal vital signs. Her height is 5’6” and her weight 135 pounds, with a BMI of 21.8. The head, eyes, ears, nose, and throat exam was normal. There was no lymphadenopathy, her lungs were clear, and her heart had regular rate and rhythm with no murmurs or friction rubs. The abdomen was soft, nontender, and had no mass or hepatosplenomegaly. Her skin showed good color and turgor with no rashes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The musculoskeletal exam: The patient’s gait was slightly stiff. The patient had warmth, swelling, irritability, and decreased range of motion in bilateral wrists; swelling, irritability, bony proliferation, and decreased range of motion in bilateral second through third metacarpophalangeal joints; and bilateral second through fourth proximal interphalangeal joints and is beginning to develop swan neck deformities. The patient had synovial thickening and bony proliferation in bilateral knees, as well as large effusions in bilateral ankles with warmth and slightly decreased dorsiflexion and plantar flexion. All other joints were unremarkable with full range of motion and no evidence of active synovitis.

Diagnosis: Rheumatoid arthritis with active disease and GERD.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Plan: Review of labs done six weeks prior showed mild anemia and elevated erythrocyte sedimentation rate and C-reactive protein. The patient’s other labs were normal. Therapeutic options were discussed with the patient, and the decision was made to add a tumor necrosis factor (TNF)–alpha inhibitor. Actions, side effects, and administration of TNF-alpha inhibitors were reviewed with patient. Laboratory studies were ordered along, with a chest X-ray. A purified protein derivative (PPD) test was placed on patient’s right forearm, and the patient was continued on celecoxib, methotrexate, folic acid, and lansoprazole. In addition, the patient was given a prescription for an occupational therapy evaluation and treatment to include finger splints. She scheduled to return to office in three days to have the PPD read and for a patient-education visit with a registered nurse to learn self-administration of TNF-alpha injections.

Page: 1 2 | Single Page
Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingE&MEvaluation and ManagementRheumatiod arthritis

Related Articles

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib Is a Safe Treatment for Arthritis

    February 20, 2017

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences